Radiopharm Theranostics Completes RAD 101 Phase 2b Trial Enrollment
Ticker: RADX · Form: 6-K · Filed: Apr 16, 2026 · CIK: 0001949257
Sentiment: neutral
Topics: clinical-trial, drug-development, regulatory-filing
TL;DR
RAD completes enrollment for RAD 101 Phase 2b trial. Big step forward.
AI Summary
Radiopharm Theranostics Ltd. announced on April 16, 2026, the completion of enrollment for its Phase 2b trial of RAD 101. This marks a significant milestone in the development of their radiopharmaceutical.
Why It Matters
The completion of patient enrollment is a critical step towards evaluating the efficacy and safety of RAD 101, potentially paving the way for future regulatory approvals and commercialization.
Risk Assessment
Risk Level: medium — While trial enrollment completion is positive, the ultimate success of RAD 101 and its regulatory approval remain uncertain.
Key Players & Entities
- Radiopharm Theranostics Ltd. (company) — Filer of the 6-K report
- RAD 101 (drug_candidate) — Drug undergoing Phase 2b trial
FAQ
What is the significance of completing enrollment in the Phase 2b trial of RAD 101?
Completing enrollment is a crucial step that allows the trial to proceed to the next stages of data analysis and evaluation of RAD 101's efficacy and safety.
What is the filing date of this 6-K report?
The filing date of this 6-K report is April 16, 2026.
What is the primary business of Radiopharm Theranostics Ltd.?
Radiopharm Theranostics Ltd. is involved in the pharmaceutical preparations industry, specifically focusing on radiopharmaceuticals.
What is the accession number for this SEC filing?
The SEC accession number for this filing is 0001213900-26-044334.
What other document is filed alongside the main 6-K report?
An exhibit titled 'RAD COMPLETES ENROLLMENT IN PHASE 2B TRIAL OF RAD 101' (EX-99.1) is filed alongside the main 6-K report.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 16, 2026 regarding Radiopharm Theranostics Ltd (RADX).